Uptake of biosimilars for TNF-α inhibitors adalimumab and etanercept following the best-value biological medicine initiative in Ireland
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Clinical Pharmacy"
DOI: 10.1007/s11096-021-01243-0
Abstract: Background There is over 10 years of clinical experience and evidence to show that biosimilar medicines can be used as safely and effectively in approved therapeutic indications as their originator biological medicines. In Ireland, biosimilar… read more here.
Keywords: medicine; adalimumab etanercept; value biological; best value ... See more keywords
AB0462 BMI IS ASSOCIATED WITH BOTH DISEASE ACTIVITY AND TNF-α INHIBITOR SERUM TROUGH LEVELS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS ON LONG-TERM TREATMENT WITH TNF-α INHIBITORS
Sign Up to like & getrecommendations! Published in 2021 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2021-eular.521
Abstract: TNF-α inhibitors (TNFi) are widely used in axial spondyloarthritis (axSpA) patients with active disease. Approximately half of patients stop TNFi treatment, often due to loss of treatment efficacy.1 TNFi serum trough levels have been associated… read more here.
Keywords: adalimumab etanercept; serum trough; trough levels; tnfi ... See more keywords